Raphael Pharmaceutical Inc. (RAPH) Financial Statements (2024 and earlier)
Company Profile
| Business Address |
SUITE 105 - 5348 VEGAS DR. LAS VEGAS, NV 89108 |
| State of Incorp. | NV |
| Fiscal Year End | December 31 |
| Industry (SIC) | 2833 - Medicinal Chemicals and Botanical Products (benchmarking) |
| More info | Complete Financial Analysis Financial Benchmarking |
Balance Sheet (Statement of Financial Position) ($ in thousands)
| 3/31/2024 MRQ | 12/31/2023 | 12/31/2022 | 12/31/2021 | |||
|---|---|---|---|---|---|---|
| ASSETS | ||||||
| Current Assets | ||||||
| Cash, cash equivalents, and short-term investments | 230 | 288 | 153 | |||
| Cash and cash equivalents | 230 | 288 | 153 | |||
| Other current assets | 107 | 43 | 269 | |||
| Total current assets: | 337 | 331 | 422 | |||
| Noncurrent Assets | ||||||
| Intangible assets, net (including goodwill) | 2 | 2 | ||||
| Intangible assets, net (excluding goodwill) | 2 | 2 | ||||
| Total noncurrent assets: | 2 | 2 | ||||
| TOTAL ASSETS: | 339 | 333 | 422 | |||
| LIABILITIES AND EQUITY | ||||||
| Liabilities | ||||||
| Current Liabilities | ||||||
| Accounts payable and accrued liabilities, including: | 224 | |||||
| Accrued liabilities | 152 | |||||
| Other undisclosed accounts payable and accrued liabilities | 72 | |||||
| Debt | 38 | |||||
| Due to related parties | ✕ | ✕ | 3 | 22 | ||
| Other undisclosed current liabilities | 34 | 272 | ||||
| Total current liabilities: | 72 | 227 | 294 | |||
| Noncurrent Liabilities | ||||||
| Total liabilities: | 72 | 227 | 294 | |||
| Equity | ||||||
| Equity, attributable to parent, including: | (267) | 106 | 128 | |||
| Common stock | 185 | 157 | 130 | |||
| Additional paid in capital | 7,392 | 5,975 | 2,665 | |||
| Accumulated deficit | (7,310) | (6,026) | (2,667) | |||
| Other undisclosed equity, attributable to parent | (534) | |||||
| Total equity: | (267) | 106 | 128 | |||
| Other undisclosed liabilities and equity | 534 | |||||
| TOTAL LIABILITIES AND EQUITY: | 339 | 333 | 422 | |||
Income Statement (P&L) ($ in thousands)
| 3/31/2024 TTM | 12/31/2023 | 12/31/2022 | 12/31/2021 | ||
|---|---|---|---|---|---|
| Revenues (Revenue from Related Parties) | 185 | 195 | |||
| Cost of revenue (Cost of Goods and Services Sold) | (9) | (31) | |||
| Gross profit: | 176 | 164 | |||
| Operating expenses | (1,272) | (3,317) | (1,629) | ||
| Other undisclosed operating loss | (176) | (164) | |||
| Operating loss: | (1,272) | (3,317) | (1,629) | ||
| Nonoperating income (expense) | (12) | (41) | 4 | ||
| Other undisclosed loss from continuing operations before equity method investments, income taxes | |||||
| Loss from continuing operations: | (1,284) | (3,358) | (1,625) | ||
| Loss before gain (loss) on sale of properties: | ✕ | ✕ | ✕ | (1,625) | |
| Net loss available to common stockholders, diluted: | (1,284) | (3,358) | (1,625) | ||
Comprehensive Income ($ in thousands)
| 3/31/2024 TTM | 12/31/2023 | 12/31/2022 | 12/31/2021 | ||
|---|---|---|---|---|---|
| Net loss: | (1,284) | (3,358) | (1,625) | ||
| Comprehensive loss: | (1,284) | (3,358) | (1,625) | ||
| Other undisclosed comprehensive income, net of tax, attributable to parent | 6,716 | ||||
| Comprehensive income (loss), net of tax, attributable to parent: | (1,284) | 3,358 | (1,625) | ||
Statements Sources
The financial statements are based on the Company's filings with the U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.